Compare · AGPU vs EW
AGPU vs EW
Side-by-side comparison of Axe Compute Inc. (AGPU) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGPU and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.38B, about 436.6x AGPU ($120.0M).
- Over the past year, AGPU is down 26.5% and EW is up 11.7% - EW leads by 38.2 points.
- AGPU has been more active in the news (8 items in the past 4 weeks vs 3 for EW).
- EW has more recent analyst coverage (25 ratings vs 0 for AGPU).
- Company
- Axe Compute Inc.
- Edwards Lifesciences Corporation
- Price
- $10.26+0.49%
- $90.83+0.31%
- Market cap
- $120.0M
- $52.38B
- 1M return
- +42.50%
- +9.41%
- 1Y return
- -26.45%
- +11.74%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 0
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AGPU
- Axe Compute Receives $317 Million in Customer Prepayments Under Global AI Infrastructure Contracts
- Axe Compute Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Axe Compute and Duos Technologies Enter into Agreements For 55 MW of New AI Data Center Capacity Across Multiple U.S. Locations
- Duos Technologies Signs Five-Year, 55 MW Hosting Agreements with Axe Compute Valued at Over $500 Million
- SEC Form 10-Q filed by Axe Compute Inc.
- Axe Compute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Axe Compute Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
- Axe Compute to Host Q2 2026 Financial Results Conference Call
- SEC Form 424B3 filed by Axe Compute Inc.
- SEC Form EFFECT filed by Axe Compute Inc.
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results